WO2007081694A2 - Derivatives of sulindac, use thereof and preparation thereof - Google Patents
Derivatives of sulindac, use thereof and preparation thereof Download PDFInfo
- Publication number
- WO2007081694A2 WO2007081694A2 PCT/US2007/000050 US2007000050W WO2007081694A2 WO 2007081694 A2 WO2007081694 A2 WO 2007081694A2 US 2007000050 W US2007000050 W US 2007000050W WO 2007081694 A2 WO2007081694 A2 WO 2007081694A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- pharmaceutically acceptable
- methyl
- acetamide
- indene
- Prior art date
Links
- 0 CC1=C(CC(**)=O)c2cc(*)ccc2C1Cc1ccc(*)cc1 Chemical compound CC1=C(CC(**)=O)c2cc(*)ccc2C1Cc1ccc(*)cc1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007800019364A CN101365461B (en) | 2006-01-04 | 2007-01-04 | Derivatives of sulindac, use thereof and preparation thereof |
EP07716225A EP1968616A4 (en) | 2006-01-04 | 2007-01-04 | Derivatives of sulindac, use thereof and preparation thereof |
NZ569430A NZ569430A (en) | 2006-01-04 | 2007-01-04 | Derivatives of sulindac, use thereof and preparation thereof |
AU2007205208A AU2007205208B2 (en) | 2006-01-04 | 2007-01-04 | Derivatives of sulindac, use thereof and preparation thereof |
MX2008008717A MX2008008717A (en) | 2006-01-04 | 2007-01-04 | Derivatives of sulindac, use thereof and preparation thereof. |
EA200870148A EA016323B1 (en) | 2006-01-04 | 2007-01-04 | Derivatives of sulindac, use thereof and preparation thereof |
CA2635093A CA2635093C (en) | 2006-01-04 | 2007-01-04 | Derivatives of sulindac, use thereof and preparation thereof |
JP2008549538A JP5337491B2 (en) | 2006-01-04 | 2007-01-04 | Sulindac derivatives, their use and their preparation |
BRPI0706283-4A BRPI0706283A2 (en) | 2006-01-04 | 2007-01-04 | compound, pharmaceutical composition and methods of compound preparation and treatment of precancerous or cancerous conditions in mammals |
IL192427A IL192427A0 (en) | 2006-01-04 | 2008-06-24 | Derivatives of sulindac, use thereof and preparation thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75584706P | 2006-01-04 | 2006-01-04 | |
US60/755,847 | 2006-01-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007081694A2 true WO2007081694A2 (en) | 2007-07-19 |
WO2007081694A3 WO2007081694A3 (en) | 2007-11-01 |
Family
ID=38256870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/000050 WO2007081694A2 (en) | 2006-01-04 | 2007-01-04 | Derivatives of sulindac, use thereof and preparation thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US8044048B2 (en) |
EP (1) | EP1968616A4 (en) |
JP (1) | JP5337491B2 (en) |
KR (1) | KR20080091134A (en) |
CN (1) | CN101365461B (en) |
AU (1) | AU2007205208B2 (en) |
BR (1) | BRPI0706283A2 (en) |
CA (1) | CA2635093C (en) |
EA (1) | EA016323B1 (en) |
IL (1) | IL192427A0 (en) |
MX (1) | MX2008008717A (en) |
NZ (1) | NZ569430A (en) |
WO (1) | WO2007081694A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010008427A1 (en) * | 2008-04-11 | 2010-01-21 | Ludwig Institute For Cancer Research Ltd. | Tryptophan catabolism in cancer treatment and diagnosis |
WO2014068461A2 (en) * | 2012-11-02 | 2014-05-08 | Mahesh Kandula | Compositions and methods for the treatment of acute inflammation |
US9365528B2 (en) | 2011-04-01 | 2016-06-14 | Southern Research Institute | Derivatives of sulindac, use thereof and preparation thereof |
WO2016099452A1 (en) * | 2014-12-16 | 2016-06-23 | Adt Pharmaceuticals, Inc. | Ras-inhibiting indenyl acetamide compounds, compositions, and uses |
EP3233794A1 (en) * | 2014-12-16 | 2017-10-25 | ADT Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
US11104658B2 (en) | 2014-12-16 | 2021-08-31 | Adt Pharmaceuticals, Llc | Method of treating or preventing Ras-mediated diseases |
EP3687972A4 (en) * | 2017-09-28 | 2021-09-29 | Medicon Pharmaceuticals, Inc. | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof |
US11186596B2 (en) | 2018-04-26 | 2021-11-30 | Adt Pharmaceuticals, Llc | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103002887B (en) * | 2010-05-06 | 2016-12-21 | 桑福德-伯纳姆医学研究所 | Relate to the method and composition of Retinoid receptor selective channel |
WO2018170410A1 (en) * | 2017-03-17 | 2018-09-20 | University Of South Alabama | Derivatives of sulindac can protect normal cells against oxidative damage |
US10329249B1 (en) | 2018-10-03 | 2019-06-25 | King Saud University | Sulindac derivatives |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT290523B (en) | 1962-01-05 | 1971-06-11 | Merck & Co Inc | Process for the production of new α- (3-indolyl) -carboxylic acids |
US3647858A (en) | 1970-05-01 | 1972-03-07 | Merck & Co Inc | Process for preparing 1-benzylidene-3-indenyl acetic acids |
US3654349A (en) | 1970-05-01 | 1972-04-04 | Merck & Co Inc | Substituted indenyl acetic acids |
US3851063A (en) | 1972-07-21 | 1974-11-26 | Merck & Co Inc | Treatment of pain,fever or inflammation |
US4423075A (en) | 1980-06-19 | 1983-12-27 | Ayerst, Mckenna & Harrison Inc. | Aldose reductase inhibition by 5-fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acetic acid |
US5401774A (en) | 1991-03-08 | 1995-03-28 | University Of Arizona | Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds |
EP0508586B1 (en) * | 1991-03-08 | 1995-05-31 | Fgn, Inc. | Substituted indenyl compounds |
US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
US5475021A (en) | 1993-12-03 | 1995-12-12 | Vanderbilt University | Compounds and compositions for inhibition of cyclooxygenase activity |
US6063818A (en) | 1996-06-13 | 2000-05-16 | Cell Pathways Inc. | Substituted benzylidene indenyl formamides, acetamides and propionamides |
HUP9904696A2 (en) | 1996-11-12 | 2000-05-28 | American Home Products Corporation | Indene inhibitors of cox-2 |
US5973191A (en) | 1996-12-30 | 1999-10-26 | Vanderbilt University | Selective inhibitors of prostaglandin endoperoxide synthase-2 |
US6071934A (en) * | 1997-03-25 | 2000-06-06 | Cell Pathways, Inc. | Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions |
CA2238283C (en) | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
US5858694A (en) | 1997-05-30 | 1999-01-12 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of cancerous lesions |
CN100436418C (en) | 1997-12-12 | 2008-11-26 | Osi制药公司 | N-Benzyl-3-indenylacetamides derivatives for treating neoplasia |
US5942520A (en) | 1998-01-27 | 1999-08-24 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines |
US6388054B1 (en) * | 1998-08-20 | 2002-05-14 | John M. Stewart | Anti-cancer compounds |
US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
US6130053A (en) * | 1999-08-03 | 2000-10-10 | Cell Pathways, Inc. | Method for selecting compounds for inhibition of neoplastic lesions |
US6235776B1 (en) * | 1998-11-12 | 2001-05-22 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
US6207700B1 (en) | 1999-01-07 | 2001-03-27 | Vanderbilt University | Amide derivatives for antiangiogenic and/or antitumorigenic use |
ITMI20030617A1 (en) * | 2003-03-28 | 2004-09-29 | Dinamite Dipharma S P A In Forma A Bbreviata Diph | PROCEDURE FOR THE PREPARATION OF AN ORGANIC COMPOUND CONTAINING A SULFINYL OR SULFONYL GROUP |
JP2004315511A (en) * | 2003-03-31 | 2004-11-11 | Taisho Pharmaceut Co Ltd | Mch receptor antagonist |
CA2562783A1 (en) * | 2004-04-26 | 2005-12-01 | Vanderbilt University | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity |
JP2006124387A (en) * | 2004-09-30 | 2006-05-18 | Taisho Pharmaceut Co Ltd | New quinoline, tetrahydroquinazoline, and pyrimidine derivative, and treating method associated with their use |
-
2007
- 2007-01-04 US US11/649,373 patent/US8044048B2/en not_active Expired - Fee Related
- 2007-01-04 WO PCT/US2007/000050 patent/WO2007081694A2/en active Application Filing
- 2007-01-04 JP JP2008549538A patent/JP5337491B2/en not_active Expired - Fee Related
- 2007-01-04 BR BRPI0706283-4A patent/BRPI0706283A2/en not_active IP Right Cessation
- 2007-01-04 EA EA200870148A patent/EA016323B1/en not_active IP Right Cessation
- 2007-01-04 EP EP07716225A patent/EP1968616A4/en not_active Withdrawn
- 2007-01-04 AU AU2007205208A patent/AU2007205208B2/en not_active Ceased
- 2007-01-04 CN CN2007800019364A patent/CN101365461B/en not_active Expired - Fee Related
- 2007-01-04 CA CA2635093A patent/CA2635093C/en not_active Expired - Fee Related
- 2007-01-04 KR KR1020087016410A patent/KR20080091134A/en not_active Application Discontinuation
- 2007-01-04 NZ NZ569430A patent/NZ569430A/en not_active IP Right Cessation
- 2007-01-04 MX MX2008008717A patent/MX2008008717A/en not_active Application Discontinuation
-
2008
- 2008-06-24 IL IL192427A patent/IL192427A0/en unknown
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP1968616A4 |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010008427A1 (en) * | 2008-04-11 | 2010-01-21 | Ludwig Institute For Cancer Research Ltd. | Tryptophan catabolism in cancer treatment and diagnosis |
US9365528B2 (en) | 2011-04-01 | 2016-06-14 | Southern Research Institute | Derivatives of sulindac, use thereof and preparation thereof |
WO2014068461A2 (en) * | 2012-11-02 | 2014-05-08 | Mahesh Kandula | Compositions and methods for the treatment of acute inflammation |
WO2014068461A3 (en) * | 2012-11-02 | 2014-12-24 | Mahesh Kandula | Compositions and methods for the treatment of acute inflammation |
US10981886B2 (en) | 2014-12-16 | 2021-04-20 | Adt Pharmaceuticals, Llc | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
US11407727B2 (en) | 2014-12-16 | 2022-08-09 | Adt Pharmaceuticals, Llc | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
US10526307B2 (en) | 2014-12-16 | 2020-01-07 | Adt Pharmaceuticals, Llc | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
US10975054B2 (en) | 2014-12-16 | 2021-04-13 | Adt Pharmaceuticals, Llc | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
WO2016099452A1 (en) * | 2014-12-16 | 2016-06-23 | Adt Pharmaceuticals, Inc. | Ras-inhibiting indenyl acetamide compounds, compositions, and uses |
US11104658B2 (en) | 2014-12-16 | 2021-08-31 | Adt Pharmaceuticals, Llc | Method of treating or preventing Ras-mediated diseases |
US11130744B2 (en) | 2014-12-16 | 2021-09-28 | Adt Pharmaceuticals, Llc | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
EP3233794B1 (en) * | 2014-12-16 | 2023-02-01 | ADT Pharmaceuticals, LLC | Indenyl compounds, pharmaceutical compositions and medical uses thereof |
EP4053105A1 (en) * | 2014-12-16 | 2022-09-07 | ADT Pharmaceuticals, LLC | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
US11198679B2 (en) | 2014-12-16 | 2021-12-14 | Adt Pharmaceuticals, Llc | Method of treating or preventing Ras-mediated diseases |
EP3233794A1 (en) * | 2014-12-16 | 2017-10-25 | ADT Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
EP3687972A4 (en) * | 2017-09-28 | 2021-09-29 | Medicon Pharmaceuticals, Inc. | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof |
US11752146B2 (en) | 2017-09-28 | 2023-09-12 | Medicon Pharmaceuticals, Inc. | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof |
US11186596B2 (en) | 2018-04-26 | 2021-11-30 | Adt Pharmaceuticals, Llc | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses |
US11680073B2 (en) | 2018-04-26 | 2023-06-20 | Adt Pharmaceuticals, Llc | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses |
Also Published As
Publication number | Publication date |
---|---|
WO2007081694A3 (en) | 2007-11-01 |
JP2009522364A (en) | 2009-06-11 |
CA2635093A1 (en) | 2007-07-19 |
EP1968616A2 (en) | 2008-09-17 |
EA200870148A1 (en) | 2008-12-30 |
BRPI0706283A2 (en) | 2011-03-22 |
MX2008008717A (en) | 2008-09-10 |
JP5337491B2 (en) | 2013-11-06 |
US8044048B2 (en) | 2011-10-25 |
IL192427A0 (en) | 2009-02-11 |
EP1968616A4 (en) | 2009-10-21 |
CN101365461B (en) | 2013-07-24 |
NZ569430A (en) | 2012-05-25 |
US20070244122A1 (en) | 2007-10-18 |
CA2635093C (en) | 2012-06-26 |
AU2007205208A1 (en) | 2007-07-19 |
KR20080091134A (en) | 2008-10-09 |
CN101365461A (en) | 2009-02-11 |
EA016323B1 (en) | 2012-04-30 |
AU2007205208B2 (en) | 2012-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8044048B2 (en) | Derivatives of sulindac, use thereof and preparation thereof | |
AU2019261938A1 (en) | Small molecule degraders of polybromo-1 (PBRM1) | |
JP2004520282A (en) | Cyanoguanidine prodrug | |
WO2020257278A2 (en) | Small molecule target bromo/acetyl proteins and uses thereof | |
US9365528B2 (en) | Derivatives of sulindac, use thereof and preparation thereof | |
CS274446B2 (en) | Method of 1-acyl-3-/4-/2-pyrimidinyl/-1-piperazinyl/propanes production | |
US8236850B2 (en) | Dimeric derivatives of artemisinin and application in anticancer therapy | |
ES2636469T3 (en) | New derivatives of pyrido [3,4-c] [1,9] phenanthroline and 11,12-dihydropyrid [3,4-c] [1,9] phenanthroline and their use, particularly for the treatment of cancer | |
US6376518B1 (en) | Acyl derivatives of 4-demethylpenclomedine, use thereof and preparation thereof | |
AU2006210831B2 (en) | Derivatives of 4-demethylpenclomedine, use thereof and preparation thereof | |
KR20180011949A (en) | Novel 2-amine substituted 1,4-naphthoquinone compounds and pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient | |
DK3186268T3 (en) | ESTERS OF STEROID LACTAM AND BIS (2-CHLORETHYL) -AMINOPHENOXY PROPIONIC ACID DERIVATIVES | |
KR20230118883A (en) | Imidazole compounds as ENPP1 inhibitors | |
NZ616076B2 (en) | Derivatives of sulindac, use thereof and preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007205208 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 569370 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2635093 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 569430 Country of ref document: NZ |
|
REEP | Request for entry into the european phase |
Ref document number: 2007716225 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/008717 Country of ref document: MX Ref document number: 2008549538 Country of ref document: JP Ref document number: 2007716225 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780001936.4 Country of ref document: CN Ref document number: 1020087016410 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007205208 Country of ref document: AU Date of ref document: 20070104 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200870148 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: PI0706283 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080630 |